Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RPRX – Royalty Pharma plc

Royalty Pharma plc
RPRX
$38.64
Name : Royalty Pharma plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $22,533,853,184.00
EPSttm : 1.75
finviz dynamic chart for RPRX
Royalty Pharma plc
$38.64
0.90%
$0.35

Float Short %

8.24

Margin Of Safety %

31

Put/Call OI Ratio

0.71

EPS Next Q Diff

-0.02

EPS Last/This Y

2.72

EPS This/Next Y

0.41

Price

38.64

Target Price

48.33

Analyst Recom

1.33

Performance Q

6.39

Relative Volume

0.62

Beta

0.42

Ticker: RPRX




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02RPRX39.520.270.1222737
2025-12-03RPRX39.620.270.0022746
2025-12-04RPRX39.150.270.0122569
2025-12-05RPRX39.740.270.0022385
2025-12-08RPRX38.690.270.0222449
2025-12-09RPRX38.080.270.0622484
2025-12-10RPRX38.240.270.0122537
2025-12-11RPRX38.810.280.1821973
2025-12-12RPRX38.380.280.4721953
2025-12-15RPRX38.520.280.2522061
2025-12-16RPRX38.380.280.1022063
2025-12-17RPRX38.310.290.0522020
2025-12-18RPRX38.420.290.0321922
2025-12-19RPRX38.60.290.1521958
2025-12-22RPRX38.870.890.046650
2025-12-23RPRX39.390.840.016882
2025-12-26RPRX39.220.762.047270
2025-12-29RPRX39.080.712.507635
2025-12-30RPRX38.990.710.007646
2025-12-31RPRX38.630.710.007644
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02RPRX39.5314.2739.54.63
2025-12-03RPRX39.6014.2757.74.63
2025-12-04RPRX39.1514.2735.84.63
2025-12-05RPRX39.7314.2779.04.63
2025-12-08RPRX38.6714.2- 4.63
2025-12-09RPRX38.0914.2729.74.63
2025-12-10RPRX38.2814.2762.64.63
2025-12-11RPRX38.8014.2777.74.63
2025-12-12RPRX38.3914.2737.04.63
2025-12-15RPRX38.5313.9760.74.64
2025-12-16RPRX38.5313.9748.54.64
2025-12-17RPRX38.3113.9757.04.64
2025-12-18RPRX38.4213.9765.34.64
2025-12-19RPRX38.6013.9767.84.64
2025-12-22RPRX38.8313.9770.44.64
2025-12-23RPRX39.4013.9782.44.64
2025-12-26RPRX39.2113.9759.04.64
2025-12-29RPRX39.0813.9755.04.64
2025-12-30RPRX39.0013.9751.34.64
2025-12-31RPRX38.6413.9740.04.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02RPRX-0.25-2.157.13
2025-12-03RPRX-0.25-2.157.13
2025-12-04RPRX-0.34-2.157.13
2025-12-05RPRX-0.43-2.157.13
2025-12-08RPRX-0.43-2.117.13
2025-12-09RPRX-0.47-2.117.13
2025-12-10RPRX-0.47-2.117.22
2025-12-11RPRX-0.47-2.117.22
2025-12-12RPRX-0.47-2.117.22
2025-12-15RPRX-0.47-2.127.24
2025-12-16RPRX-0.46-2.127.24
2025-12-17RPRX-0.46-2.127.24
2025-12-18RPRX-0.53-2.127.24
2025-12-19RPRX-0.53-2.127.24
2025-12-22RPRX-0.62-2.197.24
2025-12-23RPRX-0.64-2.197.24
2025-12-26RPRX-0.64-2.198.24
2025-12-29RPRX-0.64-2.198.24
2025-12-30RPRX-0.66-2.198.24
2025-12-31RPRX-0.66-2.198.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.17

Avg. EPS Est. Current Quarter

1.31

Avg. EPS Est. Next Quarter

1.15

Insider Transactions

-0.66

Institutional Transactions

-2.19

Beta

0.42

Average Sales Estimate Current Quarter

839

Average Sales Estimate Next Quarter

859

Fair Value

50.79

Quality Score

61

Growth Score

77

Sentiment Score

95

Actual DrawDown %

27.4

Max Drawdown 5-Year %

-49.7

Target Price

48.33

P/E

22.1

Forward P/E

8.05

PEG

0.9

P/S

9.49

P/B

2.58

P/Free Cash Flow

8.89

EPS

1.75

Average EPS Est. Cur. Y​

4.64

EPS Next Y. (Est.)

5.05

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

32.54

Relative Volume

0.62

Return on Equity vs Sector %

-15.4

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

740
Royalty Pharma plc
Sector: Healthcare
Industry: Biotechnology
Employees:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
stock quote shares RPRX – Royalty Pharma plc Stock Price stock today
news today RPRX – Royalty Pharma plc stock forecast ,stock prediction 2023 2024 2025
marketwatch RPRX – Royalty Pharma plc yahoo finance google finance
stock history RPRX – Royalty Pharma plc invest stock market
stock prices RPRX premarket after hours
ticker RPRX fair value insiders trading